Staphylococcus aureus in the airways of cystic fibrosis patients - A retrospective long-term study
- PMID: 29501453
- DOI: 10.1016/j.ijmm.2018.02.003
Staphylococcus aureus in the airways of cystic fibrosis patients - A retrospective long-term study
Abstract
Background: Cystic fibrosis (CF) is an autosomal recessive disease associated with chronic airway infections by Staphylococcus aureus as one of the earliest and most prevalent pathogens. We conducted a retrospective study to determine the S. aureus infection status of CF patients treated since 1994 at two certified CF-centres in Münster, Germany, to get insights into the dynamics of S. aureus airway infection and the clinical impact on lung function on a long-term perspective.
Materials and methods: We used data from our microbiological database collected between 1994 and 2016 for patients treated at two centres in Münster, Germany, respectively, to determine the infection status for S. aureus. Furthermore, the resistance to selected antibiotics was determined for all patients' isolates and for 15 patients on a longitudinal basis. In addition, the prevalence of adaptive phenotypes such as small colony variants (SCVs) and mucoid S. aureus was assessed.
Results: For this study, 2867 patient years with respiratory specimens (mean of 9.3 years for every patient, range 1-22 years) were evaluated for 283 CF patients (median age of 7 years at the beginning of the observation period, range 0-57 years, 51% male). 18% of patients were rarely infected by S. aureus (≤24% of observation years), 20% of patients intermittently (25-49%) and 61% persistently (≥50% of observation period). Susceptibility testing for 12969 S. aureus isolates resulted in resistance to methicillin in 9%, trimethoprim/sulfamethoxazole in 10%, levofloxacin in 14%, gentamicin in 20%, erythromycin and/or clindamycin in 30% and penicillin in 80% of all isolates. S. aureus isolates of 15 patients revealed dynamics of resistance with increase, decrease and loss of resistant isolates to the analysed antibiotics during the study period. SCVs were isolated at least once from 42% (n = 118) of patients and mucoid isolates from 2% (n = 7) of patients. In the last study year, 89 patients were infected by S. aureus only, 44 patients by S. aureus and Pseudomonas aeruginosa and 18 by P. aeruginosa only. Patients infected by S. aureus only were younger and had better lung function compared to the other two groups.
Conclusions: We determined a high percentage of patients with persistent S. aureus infection. During persistence, mostly fluctuation of resistance against various antibiotics was observed in the isolates indicating acquisition and loss of resistance genes by S. aureus. The prevalence of adaptive phenotypes during long-term persistence was high for SCVs (42% of patients), but low for mucoid isolates (2% of patients), which might be underestimated for mucoid phenotypes due to the retrospective study design and the difficulty to detect mucoid isolates in primary cultures. While patients with S. aureus only had better lung function and were younger, no difference was found between the group of P. aeruginosa and S. aureus co-infection and P. aeruginosa only with previous S. aureus infection.
Keywords: Cystic fibrosis; Mucoid phenotypes; Persistence; Resistance; S. aureus; SCVs.
Copyright © 2018 Elsevier GmbH. All rights reserved.
Similar articles
-
The prevalence of Staphylococcus aureus with mucoid phenotype in the airways of patients with cystic fibrosis-A prospective study.Int J Med Microbiol. 2019 Jul;309(5):283-287. doi: 10.1016/j.ijmm.2019.05.002. Epub 2019 May 11. Int J Med Microbiol. 2019. PMID: 31122879
-
Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease.J Clin Microbiol. 2007 Jan;45(1):168-72. doi: 10.1128/JCM.01510-06. Epub 2006 Nov 15. J Clin Microbiol. 2007. PMID: 17108072 Free PMC article.
-
Genotypic and Phenotypic Diversity of Staphylococcus aureus Isolates from Cystic Fibrosis Patient Lung Infections and Their Interactions with Pseudomonas aeruginosa.mBio. 2020 Jun 23;11(3):e00735-20. doi: 10.1128/mBio.00735-20. mBio. 2020. PMID: 32576671 Free PMC article.
-
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.Cochrane Database Syst Rev. 2014 Nov 24;(11):CD001912. doi: 10.1002/14651858.CD001912.pub3. Cochrane Database Syst Rev. 2014. PMID: 25419599 Updated. Review.
-
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.Cochrane Database Syst Rev. 2012 Dec 12;12:CD001912. doi: 10.1002/14651858.CD001912.pub2. Cochrane Database Syst Rev. 2012. PMID: 23235585 Updated. Review.
Cited by
-
A systematic review of the clinical impact of small colony variants in patients with cystic fibrosis.BMC Pulm Med. 2023 Sep 1;23(1):323. doi: 10.1186/s12890-023-02611-4. BMC Pulm Med. 2023. PMID: 37658311 Free PMC article.
-
Staphylococcus aureus Small-Colony Variants from Airways of Adult Cystic Fibrosis Patients as Precursors of Adaptive Antibiotic-Resistant Mutations.Antibiotics (Basel). 2023 Jun 17;12(6):1069. doi: 10.3390/antibiotics12061069. Antibiotics (Basel). 2023. PMID: 37370388 Free PMC article.
-
Crucial Role for Lipoteichoic Acid Assembly in the Metabolic Versatility and Antibiotic Resistance of Staphylococcus aureus.Infect Immun. 2023 Jul 18;91(7):e0055022. doi: 10.1128/iai.00550-22. Epub 2023 Jun 22. Infect Immun. 2023. PMID: 37347167 Free PMC article.
-
How Staphylococcus aureus and Pseudomonas aeruginosa Hijack the Host Immune Response in the Context of Cystic Fibrosis.Int J Mol Sci. 2023 Apr 1;24(7):6609. doi: 10.3390/ijms24076609. Int J Mol Sci. 2023. PMID: 37047579 Free PMC article. Review.
-
Biology and Regulation of Staphylococcal Biofilm.Int J Mol Sci. 2023 Mar 9;24(6):5218. doi: 10.3390/ijms24065218. Int J Mol Sci. 2023. PMID: 36982293 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
